Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...

A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Immune cells might be reprogrammed to use the body’s fructose — a naturally occurring sugar — as an energy source that supercharges them to fight cancer, researchers at Memorial Sloan Kettering Cancer ...

Professor Paula Nunes-Hasler, Assistant Professor at the UNIGE Faculty of Medicine, has been awarded INNOGAP and INNOSUISSE grants to advance research on ImmuneCell Booster compounds, a promising new ...

Medigene AG and Epimab Biotherapeutics Inc. have entered a strategic codevelopment agreement to research and develop off-the-shelf T-cell receptor (TCR)-guided T-cell engagers (TCR-TCEs) for the ...

Epstein-Barr virus (EBV), a member of the herpesvirus family, is a highly common human pathogen that can remain latent in B lymphocytes after the primary infection. Although this latent state is ...